Organon (OGN) Proxy filing summary

Executive summary

• A major acquisition by Sun Pharma is underway, with a shareholder vote expected soon and integration planning in progress, though both companies remain independent until closing.

• Leadership emphasizes transparent communication, regular Q&A sessions, and a commitment to addressing employee concerns as details become available.

• The company celebrates five years of independence, highlighting significant achievements in operational transformation, product launches, and cultural development.

• Strategic priorities focus on delivering 2026 performance, preparing for integration, and maintaining momentum into 2027.

• Forward-looking statements caution about uncertainties in transaction timing, regulatory approvals, and integration outcomes.

Voting matters and shareholder proposals

• A shareholder vote on the proposed acquisition by Sun Pharma is anticipated in the near future, which will determine the next phase of the transaction.

• Proxy materials, including a preliminary proxy statement, have been filed and will be updated as the process advances.

Board of directors and corporate governance

• Directors and executive officers are actively involved in the proxy solicitation process and will be disclosed in the definitive proxy statement.

• A culture work stream is established to align and integrate the best aspects of both companies' cultures post-acquisition.